-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 ON/tjwpPVp2rzWc3AWu9Ur54TddPb2Gho76hBtG614RUISgP+p42pe1o/ZXBZMfY
 vHqJJeZd1lcKGbcT5gM8Cw==

<SEC-DOCUMENT>0001132072-09-000225.txt : 20090522
<SEC-HEADER>0001132072-09-000225.hdr.sgml : 20090522
<ACCEPTANCE-DATETIME>20090521170406
ACCESSION NUMBER:		0001132072-09-000225
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090515
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090521
DATE AS OF CHANGE:		20090521

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADEONA PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		09846064

	BUSINESS ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108
		BUSINESS PHONE:		734-332-7800

	MAIL ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19940606
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>s22-9198_8k.htm
<DESCRIPTION>FORM 8-K, FIRST QUARTER EARNINGS REPORT
<TEXT>
<html>
  <head>
    <title>s22-9198_8k.htm</title>
<!-- Licensed to: Starkey & Henricks-->
<!-- Document Created using EDGARizer 4.0.7.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES
AND EXCHANGE COMMISSION</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington,
D.C. 20549</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FORM
8-K</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CURRENT
REPORT</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to Section 13 or 15(d)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of the
Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date of
Report (Date of earliest event reported):&#160;&#160;May 15, 2009</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ADEONA
PHARMACEUTICALS INC.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact
name of registrant as specified in its charter)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <div align="center">
        <div align="center">
          <div align="center">
            <div align="center">
              <div align="center">
                <div align="center">
                  <table cellpadding="0" cellspacing="0" width="100%">
                      <tr>
                        <td valign="top" width="31%" style="BORDER-BOTTOM: black 2px solid">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Delaware</font></div>
                        </td>
                        <td valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                        <td valign="top" width="31%" style="BORDER-BOTTOM: black 2px solid">
                          <div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1-12584</font></div>
                        </td>
                        <td valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                        <td valign="top" width="31%" style="BORDER-BOTTOM: black 2px solid">
                          <div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13-3808303</font></div>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" width="31%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(State
      or other jurisdiction of incorporation)</font></div>
                        </td>
                        <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                        <td valign="top" width="31%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Commission
      File No.)</font></div>
                        </td>
                        <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                        <td valign="top" width="31%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(IRS
      Employer Identification
No.)</font></div>
                        </td>
                      </tr>
                  </table>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3930
Varsity Drive, Ann Arbor, Michigan 48106</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
of principal executive offices)&#160;&#160;(Zip Code)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Registrant&#8217;s
telephone number, including area code: (734) 332-7800</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Former
name or former address, if changed since last report)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font> Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font> Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font> Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font> Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item
2.02.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Results
of Operations and Financial Condition</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>On May 15, 2009, Adeona Pharmaceuticals
Inc. released its financial results for the quarter ended March 31,
2009.&#160;&#160;A copy of the Company&#8217;s press release is attached hereto as
Exhibit 99.1 and is hereby incorporated by reference (the &#8220;Press
Release&#8221;).</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
information provided in the response to this Item 2.02 and the accompanying
Exhibit 99.1 are being furnished under Item 2.02 of Form 8-K and shall not be
deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, or otherwise subject to the liability of such Section,
nor shall such information be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, regardless of
any general incorporation by reference language in any such filing, except as
shall be expressly set forth by specific reference in such filing.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item
9.01.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial
Statements and Exhibits</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits.&#160;&#160;The
following exhibits are being furnished as part of this Report.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <div align="center">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="14%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibit
      </font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Number</font></font></div>
              </td>
              <td valign="top" width="65%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Description</font></font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="14%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
              </td>
              <td valign="top" width="65%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Press
      release regarding earnings issued by Adeona Pharmaceuticals Inc. dated May
      15, 2009</font></div>
              </td>
            </tr>
        </table>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td width="75%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ADEONA
      PHARMACEUTICALS INC.</font></td>
          </tr>
          <tr>
            <td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date: May 15,
      2009</font></td>
            <td width="75%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">/s/ Steve H.
      Kanzer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></td>
          </tr>
          <tr>
            <td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td width="75%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name:&#160;&#160;
      Steve H. Kanzer</font></td>
          </tr>
          <tr>
            <td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td width="75%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Its:&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      Chief Executive Officer</font></td>
          </tr>
      </table>
    </div>
    <div>&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div>
      <div style="TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT
INDEX</font></div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <div align="center">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="14%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibit
      </font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Number</font></font></div>
              </td>
              <td valign="top" width="65%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Description</font></font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="14%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
              </td>
              <td valign="top" width="65%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Press
      release regarding earning issued by Adeona Pharmaceuticals Inc. dated May
      15, 2009</font></div>
              </td>
            </tr>
        </table>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
  </body>
</html>



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>s22-9198_ex991.htm
<DESCRIPTION>PRESS RELEASE RE: EARNINGS, MAY 15, 2009
<TEXT>
<html>
  <head>
    <title>s22-9198_ex991.htm</title>
<!-- Licensed to: Starkey & Henricks-->
<!-- Document Created using EDGARizer 4.0.7.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT
99.1</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="s22-9198_alogo.jpg" alt="Adeona Logo"></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Adeona
Pharmaceuticals Announces<font style="DISPLAY: inline; FONT-WEIGHT: bold"> First
Quarter 2009 Results</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ann
Arbor, Michigan, May 15, 2009 -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a
specialty pharmaceutical company dedicated to the awareness, prevention and
treatment of subclinical zinc deficiency and chronic copper toxicity in the
mature population, today announced its results for its first quarter
ended&#160;&#160;March 31, 2009.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
conference call has been scheduled for 12:00 noon EDT on May 15,
2009.&#160;&#160;In order to participate in the conference call, please call
toll free: (877) 675-4751<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font>and
international dial-in: (719) 325-4854 passcode 4378978.&#160;&#160;A replay of
the conference call will be archived for at least 15 days on Adeona&#8217;s website at
www.adeonapharma.com.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">First
quarter and recent highlights included:</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">
          <tr valign="top">
            <td align="right" valign="top" style="WIDTH: 72pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Analyzed
      samples obtained from our IRB-approved, 90-subject blinded, prospective,
      observational study of metal dyshomeostatis in Alzheimer&#8217;s disease,
      Parkinson&#8217;s disease and normal subjects conducted during 2007 and
      2008;</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">
          <tr valign="top">
            <td align="right" valign="top" style="WIDTH: 72pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Focused
      development efforts on our zinc-based product candidates, including our
      Zinthionein&#8482; and EyeDaily&#8482; brands and manufacture of zinc-monocysteine
      complex;</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">
          <tr valign="top">
            <td align="right" style="WIDTH: 72pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Launched
      www.copperproof.com, an informational website dedicated to increasing
      awareness of the potential health effects of chronic copper toxicity,
      especially in the mature
population;</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">
          <tr valign="top">
            <td align="right" style="WIDTH: 72pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Appointed
      David A. Newsome, M.D., President of Adeona's subsidiary, HealthMine,
      Inc.;</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">
          <tr valign="top">
            <td align="right" style="WIDTH: 72pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Entered
      into an agreement to acquire Colwell Clinical Laboratories, Inc., an
      independent Southern California CLIA-certified clinical
      laboratory;</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">
          <tr valign="top">
            <td align="right" style="WIDTH: 72pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Adopted
      a Stock Repurchase Program authorizing the repurchase, from time-to-time
      of up to $1 million of the Company&#8217;s common stock, up to a maximum of four
      (4) million shares at prices of up to $5.00 per
  share.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Steve H.
Kanzer, CPA, JD, Chairman of the Board, President &amp; Chief Executive Officer
of Adeona, commented, &#8220;During the first quarter of 2009, we analyzed samples
from our 90-subject observational study comparing serum markers of metal
dyshomeostasis in Alzheimer&#8217;s disease, Parkinson&#8217;s disease and normal
persons.&#160;&#160;We found highly statistically significant differences in
serum copper status between Alzheimer&#8217;s patients and normal subjects, as well as
the first evidence of an apparent subclinical zinc deficiency in Alzheimer&#8217;s
disease patients.&#160;&#160;We currently intend to announce such results of
this study in the first half July and intend to acquire a CLIA-certified
laboratory to develop and launch a series of diagnostic products and services
based on such findings.&#160;&#160;Our President of our HealthMine subsidiary,
David A. Newsome, M.D., pioneered the use of oral zinc therapy for the 17
million U.S. persons with age-related macular degeneration (AMD), such that oral
zinc therapy is now the standard of care for AMD.&#160;&#160;We see a similar,
perhaps more significant opportunity for our oral zinc therapy products in
Alzheimer&#8217;s disease and its predecessor, mild cognitive impairment (MCI), which
together affect an estimated 20% of persons over the age of 65.&#8221;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Financial
Results for First Quarter of 2009</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The net
loss applicable to common shareholders for the quarter ended March 31, 2009 was
$1,113,275, or $0.05 per share, compared to a net loss applicable to common
shareholders of $3,089,456, or $0.15 per share, for the comparable period in
2008. The decrease of $1,976,181 in net loss is due to the significant
downsizing and cost saving measures initiated at the end of the first quarter of
2008.&#160;&#160;Research and development expenses decreased by $1,628,626 for
the quarter ended March 31, 2009 as compared to the same period last year. The
decrease primarily relates to a decrease of approximately $837,000 associated
with the development of our licensed clinical drug candidates, a decrease of
approximately $445,000 in stock based compensation charges and a decrease in
salaries and related taxes of approximately $296,000. General and administrative
expenses decreased by $409,138 for the quarter ended March 31, 2009 as compared
to the same period in 2008 which is primarily due to a decrease in salaries and
related payroll taxes of approximately $100,000, a decrease in allocated
overhead expense of approximately $96,000, a decrease in stock based
compensation charges of approximately $71,000 and a decrease in professional
fees of approximately $43,000.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At March
31, 2009, Adeona had cash of approximately $5.3 million, compared to
approximately $5.9 million at December 31, 2008. The decrease of approximately
$567,000 during the first quarter of 2009 is all attributable to net cash used
in operations.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">About
Adeona Pharmaceuticals, Inc.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Adeona
Pharmaceuticals, Inc. (AMEX: AEN) is a specialty pharmaceutical company
dedicated to the awareness, prevention and treatment of subclinical zinc
deficiency and chronic copper toxicity in the mature population. Adeona believes
that such conditions may contribute to the progression of important degenerative
diseases, including, dry age-related macular degeneration (dry AMD), Alzheimer&#8217;s
disease (AD) and mild cognitive impairment (MCI) in susceptible
persons.&#160;&#160;Adeona is also developing a number of late-stage clinical
drug candidates for the treatment of rheumatoid arthritis and multiple
sclerosis. For further information, please visit,
www.adeonapharma.com.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
release includes forward-looking statements on Adeona's current expectations and
projections about future events.&#160;&#160;In some cases forward-looking
statements can be identified by terminology such as &#8220;may,&#8221; &#8220;should,&#8221;
&#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221;
&#8220;believes,&#8221; &#8220;estimates,&#8221; and similar expressions. These statements are based
upon current beliefs, expectations and assumptions and are subject to a number
of risks and uncertainties, many of which are difficult to predict and include
statements regarding designing additional clinical trials for oral dnaJP1,
Zinthionein, flupirtine, or Trimesta. Adeona is at an early stage of development
and may not ever have any products that generate significant revenue. Important
factors that could cause actual results to differ materially from those
reflected in Adeona's forward-looking statements include, among others, a
failure of Adeona's product candidates to be demonstrably safe and effective, a
failure to obtain regulatory approval for the company's products or to comply
with ongoing regulatory requirements, regulatory limitations relating to the
company&#8217;s ability promote or commercialize its products for awareness,
prevention, diagnosis or treatment of subclinical zinc deficiency and chronic
copper toxicity, to a lack of acceptance of Adeona's product candidates in the
marketplace, a failure of the company to become or remain profitable, Adeona's
inability to obtain the capital necessary to fund its research and development
activities, a loss of any of the company's key scientists or management
personnel, and other factors described in Adeona&#8217;s report on Form 10-K for the
year ended December 31, 2008 and any other filings with the SEC.&#160;&#160;No
forward-looking statements can be guaranteed and actual results may differ
materially from such statements. The information in this release is provided
only as of the date of this release, and Adeona undertakes no obligation to
update any forward-looking statements contained in this release on account of
new information, future events, or otherwise, except as required by
law.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
Further Information Contact:</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Steve H.
Kanzer, CPA, JD</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chairman
and Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(734)
332-7800 x39</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
  </body>
</html>



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>s22-9198_alogo.jpg
<DESCRIPTION>ADEONA LOGO
<TEXT>
begin 644 s22-9198_alogo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@`!`3$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8T+C`P`/_;`$,``@$!`0$!
M`@$!`0("`@("!`,"`@("!00$`P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H*
M"@H&"`L,"PH,"0H*"O_;`$,!`@("`@("!0,#!0H'!@<*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_``!$(`*0`
M^@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/WTHHHH`****`(YG\N>+G[[%<?AG^E254U=Q%'#-T*7*<^@)P?T
M)JW7+2JWQ-2F^EG\FK?FF4U[J84445U$A1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`9WBMRFA3LOW@A
MV^QP<5?BD6:)94/#*"/H:SO%9W:6(<9\R95Q^O\`(5+X9G-SX<L+@]7LXR?K
MM%?.T<5;BFKA^]*+^<9-/_TM&SC^X3\_Z_(O4445]$8A1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444$X&3
M0!B>,KD1FQM\XW3R.<>B0R'^>*?X`?S/!FG-_P!.P'Y<5D>.-05]<DA1LBQT
M*YF//&YQL6M/X;[O^$(T_=_SR/7_`'C7Y9E&9+&>)N)I1=U&G42^3PL7_P"3
MJ:^3.^I#EP,7YK_V[]+&Y1117ZF<`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%9NN7Y^U6V@V[?O;MB9,'[
MD*\NWMG[H]S[5<O[ZVTRREU"\E"10H6=CV`KA)->N8_#NJ>/[T;)]1/V734)
MYCBY''ZG_@-?"\:<48;):2PSE[SC*I4MO&A35YOR<W:E#KS3NOA9U8:A*J^;
MY+U>WW;OT*.L:J-0L?$OB)3E)YHK.V;U4-SC\%!_&NX\`QF+P9IRD?\`+LI_
M/G^M>:ZZO]E^`M)TL\27DKW<@]ONK^E>J^'K8V>@V5J1S':QJ?KM%?EOA+4Q
M.-XPQ%:O\<,-!S_QXFI+$OYKGY?+EMT._,%&.&26W,[>D4H_H7****_HP\8*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`**9<7$-K`]S<2!(XU+.['@`=37+7'CF:'PU>>,9%*1R.8=+@;^+L'/J2<
MGV"UX&=<295D/^]3L^2=1^5.FKRF_*[C%=7*22ZM:TJ-2K\/=+YLS?B-K5QX
MFU^V\`:/(<-,/M;+Z]<'V4<G_P"M67\0)4U7Q%8>!=&_U%EL@4+_`'S@$_@,
M?K3_```!HVD:E\1-4.^15:.V+]7D/4_B2!^=4_A[E=0U#QIJ7SK80-*6;^*5
M\@?UK^3\US/%<3SI?7'R5,UFJDU_SYP%!MQCY*7+.HVOBY$^I]#3IQH)\NJI
MJR\YO^DA/&C1ZSX\AT*S_P!3;/#90@=@"`?U)_*O7``H"J,`#@5Y!\,[676?
M'<-U.=QC9[B4GN?7_OHBO7Z_4_`GVF:4,USZ<>7ZS7LEVC!7BEY+GY5Z'!FM
MJ;IT5]E?G_PP4445^^'D!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`'(?&#59X=(MM`LV(DU"<*<=U!''XDBN:^)\Y
M6]T_P5IP)2Q@1-B_Q2,`!^F/^^C3UUA?$WB+PO/<2[C,[N03U(G<D?\`CHJ+
MPUY/B7XJSWTT@,<%Q+.Q)Z*APOZXK^/N+\VK\99C6IX=M+'UL+AX7^S1C3C6
MG]\ZL92]#Z+#0CAH)O["DWZWLOP0_P")=Q'HNFZ=X%LW&VUA$ESC^*0_Y)_$
M57UP?\(Y\/['0U^6?4Y#=7([[!]T?R_(U2B\SQUX]&6R+R\R?]F,?X**;X_U
MA=9\47$L)_<PGR8`.@1>./QR?QKX/.LZI5Z&:9U1TA4<<'AE_+2BES6]*481
M?_7YG92I-.G2?3WI>O3\?R.J^!NE8CO=:=>I6&,_JW_LM>@5C>`-(_L7PE9V
MC+AWC\V7_>;G],@?A6S7]A>&>1/AS@;`X.2M/D4Y?XI^^T_2]OD?.8ZK[?%3
METO^6@4445]V<@4444`%->:&,[9)54^A;%.K^7S_`(/'O$&O:7_P5<T"VTS6
M[RVC/P8TAC'!<NBY_M#4^<`]>*`/Z@P01D&BN)_9J=Y/V<_`#NQ9F\$Z422<
MDG['%7;4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`>!V
M]W/X9^*FF>'[@E3I_BF6U7/_`#RG`>#\\O\`E6=\-?%ALO#/C;Q.TIW6=BL"
M-GHTTC+_`$KJ?VGO"]WI$UG\4M&@+-:R0_;%4='AD\R&3ZG]Y#]9E]*\:DUN
M'1_AO\4+&"7A/$%@L;C^*)IIF4_3`!_&OY2S_(9\.Y_*"6E)8FI!_P"+"RC2
MM_A5**?FF=\<2W&SZV_.YW_PB\4C3O#_`(C^(%P^%TO3Q#;DG_EO*=J_Y]ZS
M/AQJL_C#QII_A])"PN+@>;_N#YF/Y`UR.I>(3X:_9;TD"3;+XC\1SSL<\M%`
MNS'TW8-=A^PQILGB'Q3JWBV<;H].M$@B)Z>9*221]%0C_@5?&9;PS#-L[R/(
M7&\%%5:B[NH_:S?SHQIQ^1T?7914YIZO^O\`,^FP`H"@<#I6/XW^(7@'X9:#
M)XI^)'CC1_#VF1'$NHZYJ<5I`GUDE95'YUL5^/7Q]_X-5=4_;6_;/\=_M#?M
MB?\`!0#QMK'A+5O$MQ=^#?#%@[7-[IMA*WF+:FYO&DC@2,DQK'%$1L13N!)`
M_N#8\@_2#0O^"C'_``3W\4:XOAGPU^W=\&M1U)W*)I]C\3])FG9@<$"-+@L3
MGC&*]CAFAN84N+>59(Y%#(Z-D,#R"".HK\<OB[_P9<?\$_\`7_`UW8_!;X^_
M$SPYXC\ECI^HZS>V>HV@EQ\OFP+;Q,R9Z[9%/OVKX\_X(&?M[_M:?\$RO^"I
M3_\`!(7]J/QG=:IX.U+Q;<>$1I-W?//!H>LAF%K<V#2<I!.X1#&-JLMPLFT,
MN"`?TI445_.Y_P`%F/\`@L;^V+_P4?\`V[4_X))?\$N_%6HZ9H;^(V\-ZCJW
MA^^:VN?$VHHS+=%KI#NAT^`))N*D!UBDD8LA50`?O+XQ_:M_9<^'FO2>%?'_
M`.TEX!T+5(CB73=8\8V5K<(?0QR2AA^5?S0?\'A/B?PUXQ_X*E>&O$7A'Q#8
MZKI]S\%-':WOM-NTGAE']H:GRKH2K#Z&OT._9G_X,SOV%O"?@&U?]J_XP^.?
M&_B^>`/JUQH.IQZ9IT4QY984\IY7`.1O=\MUVKG`_'__`(.#?^"<'P(_X)=_
MMVV7[.W[.NL>(;SP]J/@&QUX?\)+?1W%Q#-/=7D+1J\<<8*!;=",@G)/)XP`
M?UL_LT?\FX?#_P#[$C2O_2.*NVKB?V:/^3</A_\`]B1I7_I'%7XM?\'&/_!7
M#]J'XJ?M;Z5_P1A_X)S:]J-EK^JW]EI7C75]`NS!>:AJ-Z$,6E13J08(4CD1
MIY`P^\R,56.0,`?L'\2/V\_V&_@WXD?P;\7/VR_A5X7UB.0I+I7B'XA:;97,
M;#J&BFF5E_$5WW@'XD_#KXK^'(O&'PM\?:+XETB9B(=5T#58;RVD(ZA98693
M^!K\>/V<_P#@R^_8RT;X76B_M6?'OQ[XC\;75L'U6Z\)W]O8:?;3L,LD*2V\
MLDBJ<C>[`MC.U<[1\/\`[=7['G[8_P#P:Q_M:>#_`-I+]CCX]ZMKOPU\6WK1
M0QZH"D=Z\.'ETG58(R(IMT9+1S*%;&\J(VCR0#^H&BO-/V.?VH?`/[:G[+O@
M;]JCX9;TT;QOX?@U*WMI7#/:2,-LULY'!>*59(FQQNC-?E5_P=2?\%L/BE^R
M#;:3^P-^R1XRN-#\;>*=&&I>-?%&ES%+S2-.E=D@M;9U.8IYBDC,XPZ1A-N#
M*&`!^JOQ5_;0_8[^!.M_\(S\;_VL/AIX-U+C_B7^*_'>GZ=/R,C]W<3(W3GI
M76?#GXK?"[XQ>'E\7?"/XDZ!XITIVVKJ?AS6(+ZW+>@DA9ES^-?BM_P3O_X-
M!?@%XL^`FD_%K_@H]X^\:ZG\0O%=DFI:CX>T+6$M(M&:<"00S2O&\EQ<C=^\
M8L%#EE`;&]OE/_@J#_P3E_:9_P"#:/\`:`\'_MI?\$]OV@O$K>`?$.I_8=^I
M2AI+:[13+_9NHI&%AO;>:-9&1B@/[MP0K*CL`?TZ4C,J*6=@`!DDGI7@O_!,
MG]NWP5_P4B_8I\%?M:>#;)+&77[`Q:_HZR[_`.S-4A8Q75MGJ56124)P6C>-
MB!NQ7XR_\'J7QQ^,WA7XT_"7X-^%_BMXATWPGK'@B]O-8\-Z?K$T-E?SB\*"
M2>%&"2D*,#>#@9QU-`'[=^//V^?V%?A9?2:7\3?VT?A/X>NH6*RVFM_$33+6
M56&<J4DG#9X/&,UK_"']KO\`90_:"O#IWP&_:<^'OC6Y5"[6WA/QG8ZC(JCJ
M2EO*Y&.^1Q7XR?\`!,K_`(--OV#?VBOV+OAG^TS\>_C%\2-3U?X@^"=.\03Z
M=H=_:6%K8_:[=)A"FZWE=]N_&\M\V,[5SBO)O^"S?_!L'X5_X)\_L[ZC^W3^
MP)\;O&,D7@*6&^\0:#KUY&;VTMO,5/MMG=VR1,K1,RLR,N=NY@X*[6`/Z-Z*
M_*S_`(-8?^"L'Q:_X*$?LT>*?@K^TEXFEUSQW\*KFT1?$=VV;C5]*N5D$#SG
M^.:)X9(VD/+J8B<MN8_<G_!1W]FKXN?M>?L8>./V?/@-\<-2^'7B_P`06$2:
M'XMTS4)[5K25)XY"CR0?O!%(BM$^WG;(<4`=;\5_VMOV4_@->?V=\<OVF_A[
MX,N,`^1XL\:6.G/@]#MN)4/-2_"/]JK]E_\`:`GDM?@-^TAX"\;2Q(6EC\(^
M,++4F10<$D6\KX&>]?D_\%_^#+K]CC3M&.H_M._M3_$?QIXCNOWFH7F@M:Z9
M;&4\LP66.XE8DD_,TF3UP*^8?^"QO_!LMIW_``38^`M[^WW_`,$_?V@?&1C\
M`7$%[KFD:Q>(NI6$+2I$+VRO+5(F!B9U+(5R$+.'^7:0#^CNBOS@_P"#9K_@
MJ5\1O^"E7[$^IZ;\>M8_M+XA_##5X=(U[6&0!]5M)8B]G>28X\U@DT;D#YF@
MW]7-?H_0`4444`5M9TBPU_2KC1M4@$EO<Q&.5#Z'T]#W!]:^,OC-X0U+X9W/
MC[P)=ON2Y\/6.H64H&!*EM=1Q`CU(B<;O<-Z5]K5X_\`M@?#:#Q3X,A\76\(
M%QIJ36MW+_TY7,9AE)]HV9)O81&OA^/,@AG&42JP7[RFI6?]V47"?W1DVO3S
M)E=*Z/EOXTZ\;3X+?"S3(WPAT2]N2,]6>Z;)_P#':^FOV"/#W]E?`.#7)$Q)
MK.HSW))'.Q2(E'T_=D_C7QO\8-2FN/@G\-+J=2LEI::IIUP&&"DD5X7VGW"R
MK7WY^S;I":'\`O!^GHFW'AZUD8?[3QAR?S8FOS3PXP$:_&]7%R7\/#44O)NE
M27X)-$PFY.QVU?/?[=?_``5,_88_X)P>'H=8_:P^.NG:'?7D)ETSPU:*UWJM
M\N2-T5K$#)LR"/,8+'D8+"NZ_;(_:"L_V3_V3/B3^TS?:>+Q?`?@?4]=CLBV
M/M4EM;22QPY[;W54S_M5_.5_P;V_L:6W_!;S_@HS\2_VO/\`@H)J<_CVQ\&Q
M6NL:[I>J2LT.K:I>RRK9P2KG`M(H[:X(@&%Q'$F-FY3_`$&:'WZ/^#K'Q;\?
MM6N-(_X)U_\`!)?XQ?%N.*4Q+J<J-;0AO5Q9V]V$'^\ZGZ5^1^I?%KXV_&W_
M`(..O!WQ<_:%^"4WPU\;:W\>_"EQKO@F:=GDTF3SK%5C9F"L28U1SD`_/T%?
MUQ>%?"?A;P+X=L_"/@GPU8:/I.GP"&PTS2[-+>WMHQT2..,!44>@`%?RU_MR
M?\K:R_\`9Q/A#^6F4`?TA?\`!0SXVZI^S=^PC\8?CSH-WY&I>%/AMK.HZ5-N
MQLNX[.4P'/\`UUV5^!'_``9;?!+1?'O[=7Q-^/WB"V6ZO/!/@%+;399AN:&Y
MU&YVM,">C^5;S)GTE;UK]S/^"OG@'5?B?_P2W_:`\$Z'#)+>77PFUM[>*(9:
M1HK228(!W)\O&.^:_%+_`(,D/B)HFD_M2?&WX5W5PBW^N^!-.U.SC)&7CL[Q
MXY,>N#>QT`?T=5_+A_P>6_\`*6+0/^R+:/\`^G#4Z_J/K^7#_@\M_P"4L6@?
M]D6T?_TX:G0!_2Q^S2RK^S?X`9F``\$:422>G^AQ5_-;_P`&_'CGP=^T3_P<
M*^,_VL?C=XHT^S6T3Q?XR74=;O8X(8KBYN/LZDO*0%VI?-@9XVC'`K^E#]FZ
M&.X_9K\`P3+E'\#:4K#/4&SB!K^2O_@EA^P3^S[^TE_P6-D_8(_;,FURTTJ7
M7/$.DM'HVI+93MJ=CY[I$SLCX5OL\BE0`Q)&"*`/Z=_BM_P63_X)5_!4R)\0
M?V_?A=#+#D2VVF>*H-1F4CJ#':&5\^V,U^1'_!RE_P`%KO\`@F)_P4`_88C_
M`&<_V:OBMJ/BSQ?IWCC3]8TVYC\+WEK:QQQ)/%,?-N8X^J3$``')QZ5^C/PM
M_P"#9C_@BS\+/+FB_8\M]?N(Q@7'BGQ+J-]N]S&TXB/_`'Q7TE\+/^">?[!G
MP1\I_A%^QA\+?#LL)!2ZTKP)813Y'0F41;R?<DF@#X;_`.#0CQOKOBK_`()`
MV>@ZT)O*\.?$76K#36ES@V[^3=?+GMYEQ+7Y!?M87Z_MD?\`!T[=>&_&C_;-
M/N?VE=*\.S03`,CV.G7EO9F+!XVM';$?\"-?U@6]O;VD*V]K`D<:*`D<:@*H
M'8`=*_DY^)]D/V=O^#JV:?QCF"WB_:OM+\R3#:%M[_5(YXG.>WEW*'/3'-`'
M]9(``P!7Y]?\'1/PVTKXA_\`!%;XJWFHVJR3>&[C1]8L)"!F&6/4K>(L,],Q
MS2+]'-?H+7P9_P`'-/B_3?"/_!$[XT#4;A$.J6NDZ?;!CR\LFK6>%'OA2?H#
M0!\9_P#!DC\5]6UG]FKXV?!6\N6:T\/^---U>QC+<(U[:R12X';_`(\D/XU\
M_P#_``>W_P#)V?P4_P"R=7W_`*7FO:_^#(3P%JEE\'?CY\3[BW*V>H^)=%TR
MUE(.'DM[>YEE'IP+F+_OJO%/^#V__D[/X*?]DZOO_2\T`?M9_P`$</\`E$]^
MSA_V17PW_P"FZ&J/_!;$`_\`!(_]HO(_YI'K7_I,]7O^".'_`"B>_9P_[(KX
M;_\`3=#5'_@MA_RB/_:+_P"R1ZU_Z3/0!^.'_!D03_PT=\=AGC_A"=)X_P"W
MR6OZ+I)(X8VFFD5$1269C@`#J2:_G0_X,B/^3C_CM_V)&D_^EDM?3W_!X?\`
M\%!/BA^SC^S/X(_9$^$'B:YT>X^+4]_+XMU"QF,<[:1:"%3:!@<JD\DX#XQE
M(2ARLC`@'T!^VK_P<_?\$MOV/?$=W\/-%\?:K\4O%-G,8)](^&]FEW#%,#M\
MMKR1T@)SP1&\A!XQGBOB[_@H!_P73_;\_;._82^*_@GP'_P18^(?AKX;Z_X$
MU"WUOXB^++JZ2+3[!X6WW85K*.-MB_-Q*PR*^H/^#:O_`()$?LX_LN_L1^`?
MVN/%OPWTO7/BO\1="A\02>)M5LTGFT>SN5\RVM;3>#]GQ"R,[KAW=V!8JJJ/
MJ3_@M=_RB0_:+_[)%K7_`*2O0!^3O_!CC-*-5_:7MQ(=C6_A%BF>"0VL@']3
M^=?T!5_/W_P8Y?\`(:_:6_Z]?"/_`*%K%?T"4`%%%%`!4.HZ?9:MI\^EZE;)
M-;W,+17$,@RKHP(93[$$BIJ*32DK,#\\OVJ_AIJ'P_T'Q%X'N5=QH/B>/6-/
MF?K-9WL?DRR9[GSH8-V.`TN*^Y?@A=17OP8\)74``1_#5B5"]!_HZ<5QO[67
MP4M_BAX+FU6TMP;RUL)[6ZVKDS6<@!8>K&*18[A1W:':/O4_]B?Q'/KO[..@
MZ=J(VWVAK+I-_$3DQR6\AC`/_``A_&OSK(<H61<8UZ:7N5:=XO\`P2V^2FHI
M=HW,(1Y*K0[]N;]GJ?\`:R_8T^*?[,]E?I:77CKP%JNBV%W*?D@N9[61(9&_
MV5D*,?8&OYO/^#>K_@H5X?\`^"(_[<_Q._9O_;Z\-:IX+TOQ?'::3XFO+O3Y
M'DT'5+"68V\DT:`LUNR75P"Z!OOQN,IDU_4Q7@O[8?\`P3!_8'_;Y2*;]K+]
MF'PWXLO[>$16VN20O:ZE#&.0BWELT<^P$DA-^W)/'-?HQN9\'_!77_@EO<>'
M1XJB_P""A'P>^Q-!YP9OB!8+)MQG_5F7>#[;<^U?S<?'#XZ?"?\`:6_X.@-&
M^.'P-\:6WB+PIKW[0OA231]:LT=8KM(Y=/A9TWJI*[XW`..<9&00:_;"/_@U
M`_X(KQZE_:!^`?B1D\PM]E;Q_J7E8_N_ZW=C\<^]?27[*/\`P2)_X)L?L2:O
M!XG_`&:OV0/".@ZW;#_1_$5S:OJ&I0YZF.[O&EFCSWV,H_"@#Z)U#3['5K"?
M2]3LX[BVN86BN+>9`R2QL"&5@>"""01[U_*Q^TA\"/VF/^#8O_@KWI7[2'PY
M\&7FJ_#276[F7PC>R%Q::WH-SD7&D33`$)<Q1MM^;G?%%,%(P*_JMKF?B_\`
M!?X1?M`^`;[X6?'+X9Z%XN\-ZD@6^T/Q%I<5W;38Y!,<BD;@>0PY4\@@C-`'
MQY^S_P#\'(7_``1]^/'P]M/&UQ^UUHO@N\E@5K[PYXX22PO;*3&3&VY3'+@\
M;HG=3ZU^!?\`P=`?MD_LU_MO_P#!22Q^*G[*_P`4K3QAX<TOX:Z;HUSK-A;S
M)";R*[OI9$0RHI<!9X_G4%3DX)P:_<SQM_P:N_\`!%7QIKLNNQ?LT:KHWG,6
M:ST3QOJ<,`).3M1IFVCV&`.P%>F_LX_\$!_^"1?[+6OV_B[X9_L6>&KO6+20
M26VI^+);C6I(G'W71;Z26.-P>0RJ"#R#0!]'?LT?\FX?#_\`[$C2O_2.*OY[
M?^#DK_@G+^T-_P`$_P#]O^T_X*^_LC:9>Q>'-8\36GB'4M5TRV,@\,^)(I$9
MI)U`.(+F11)N;Y6DDEC;&Y`W](ZJJ*$10%`P`!P!5;6]#T7Q-H]UX=\2:/:Z
MAI]]`\%[8WUNLL-Q$PPT;HP*NI!(((((-`'Y;_L0?\':O_!-?X[?"_3Y_P!J
MOQ==_"3QM#:HNMZ=?Z-=WFG33@8:2UGMHY3Y;'D+*%=<X^;&X];\?_\`@ZW_
M`."//P;\-3ZGX&^,NM_$;4UB)M='\(^%[M&E?'`::\2"-!GJ2Q(]#79?&K_@
MV>_X(R?&_P`23>+-3_9&M_#UY<R&2X7P9KU[I=NQ))XMX91#&.>B(HJQ\%_^
M#:W_`((Q?!'6(/$&D_L;:=X@O+=@T3^,]:O=6BR#GYK>XF:!_P#@49H`^M/V
M:_CYX&_:F_9^\&_M&_#2Y\W0O&WARTUC3=S@M&D\2N8GQQO0DHP[,I':OPC_
M`.#O/_@F+\3?#GQGTC_@JK\"-!O)],N;&ST_XC3:7$QETF_M<)9ZDQ7E8WB$
M4)?HCV\>3^\&/Z!O#OASP]X0T*T\+>$M!LM+TS3[=8+#3M.M4@@MHE&%CCC0
M!44#@```5+JVDZ5K^EW.AZ[IEO>V5Y`T-W9W<*R13QL"&1T8$,I!(((P0:`/
MR]_X)Q?\'3'_``3S^/O[/.AO^U]\9[/X9?$K3=,C@\4V&M6%Q]COKB-`'NK6
M:*-T*2$;Q$Q#H6*X8`,WYZ?\'%G_``6L\%?\%7=1\%?\$]O^"=NFZYXPT$^)
MXKS4M4M-*FCD\2:IAHK2TM('42M$GF2,6=5WN4P`(]S?JU\:/^#8[_@C)\:_
M%<_C*^_94_X1R[NIC+<P^#?$5[IMJ[$Y.VVCD\F(=ML:(/0"O9_V*O\`@D)_
MP3I_X)\:DWB3]EG]F31=$UZ2$Q2>*+Z6;4-3V$894N;IY'A5A]Y8RBMCD&@#
MG/\`@B%_P3QN/^"9O_!/'PA^SUXG$#>+[QI==\=S6[!D_M6ZVEX58?>$,:Q0
M!APWD[AC=BOQW_X/;_\`D[/X*?\`9.K[_P!+S7]']>!_M??\$O/V"_V]_$^D
M>,OVN_V<],\;:GH-@]EI%W?ZC>0FV@=][(!;S1@@MSD@F@#(_P"".'_*)[]G
M#_LBOAS_`--T-4?^"V'_`"B/_:+_`.R1ZU_Z3/7T#\*/A9X`^!WPRT#X.?"K
MPW%H_AGPOI%OI>@Z5!([I9VD$8CBB5I&9B%10,L2>.2:9\7OA)\.OCU\+]>^
M"_Q<\,1:UX8\3Z7-IVO:3/*Z)=VLJE9(F:-E8`@D94@^]`'\^/\`P9$?\G'_
M`!V_[$C2?_2R6OH3_@\O_8:^*/QI^`?PZ_;%^&/ARZU:U^&4VH6'C*VLH3))
M:Z?>&!H[PJ.?*CEA*NW\/G*QPJL1^FG['_\`P3$_80_8&U_6O%'[(7[.VF>"
M;_Q#9Q6NLW-AJ%Y,;J&-RZ(1<32``,2>`#S7NMW:6M_:R6-];1S0S1E)H94#
M*ZD8*D'@@C@@T`?D;_P0*_X+_?L)>+?V&_`'[,G[2OQTT+X<>/\`X=^'[?P_
M+%XMO%LK/5;6V016]S!<R8BR8E0.C,K!U8@%2"?5?^"T7_!5C_@FYJ__``3,
M^-/PO\+_`+;7PXUWQ%XL^'6IZ7X>T7PWXH@U*XO+N:!DCC"6K2%<L1\S84=2
M0*[_`./W_!N)_P`$<?VB?$=SXP\4?L=Z9H>IWDADN;GP7JMWH\;L3DG[/:RK
M`"3G)$8)S7*^!/\`@UH_X(I^!]3359OV7+_6VCD#I#KOC;5)HLCU19U##V;(
M/>@#X'_X,<O^0U^TM_UZ^$?_`$+6*_H$KB/@-^S7^SY^RWX+7X=_LX_!7PQX
M'T0,'?3?#&BPV<<K@8\R3RU!D?'5WRQ[FNWH`****`"BBB@`(!&".#7F'@OP
MVGP<^,^I:):)Y>@^,Q]LL%`PEOJ,28DB]O,A"L/^N!ZDUZ?6;XK\-6OBK1WT
MR:4Q2JZS6ET@^:WF0ADD7W#`''<9!X)KCQ>&59PJ1^.#O'[K-?--KRT?0F2O
MJ:5%4]$OKJ\L@FI1I'>0@)=QQDE0^.2I/53U'L>><@7*ZXR4E=%!1113`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@"K=1K%>0W48VNS^6Y'\2X)P?H>GX^IJU114QW8@HHHJAA1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
